TH1-like TREG cells accumulate in tumors and tumor-draining lymph nodes and interact with CD8 T cells and CXCL9-producing type 1 dendritic cells (DC1s) to suppress anti-tumor immunity through a variety of different mechanisms, including inhibition of antigen cross-presentation, downregulation of costimulatory molecules, and suppression of pro-inflammatory cytokine production (59–61). Here, CXCL9 is linked to neoplasm.